Transdermal Naltrexone for Opiate Addiction and Alcoholism
Transdermal Naltrexone for Opiate Addiction and Alcoholism
批准号:
8253142
负责人:
Audra L. Stinchcomb
金额:
$53.78万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2013-11-30
关键词:
AbscessAdverse effectsAlcohol abuseAlcohol dependenceAlcoholismAmericanAmphetaminesAnalgesicsAnimalsBlood CirculationCellulitisClinicalClinical TrialsDataDeglutitionDevelopmentDiagnosticDoseDrug FormulationsDrug KineticsDrug abuseDrug usageFDA approvedFamily suidaeFundingHealthHeroinHeroin AbuseHeroin DependenceHumanIn VitroIndividualInjection Site ReactionInjection of therapeutic agentInvestigational DrugsInvestigational New Drug ApplicationLeadLiverMethamphetamine dependenceMethodsNaltrexoneNarcotic AntagonistsNecrosisNeedlesOpiate AddictionOpiatesOpioidOralPainPainlessPatientsPharmaceutical PreparationsPharmacogeneticsPhasePhase I Clinical TrialsPhysiciansPlasmaPopulationPreparationPropertyPublic HealthPuncture procedureReportingResearchRestScreening procedureSkinStagingStomachSubstance-Related DisordersSurveysSyringesSystemTabletsTestingTherapeuticToxic effectToxicologyTranslational ResearchUnited StatesUpdateVisitWomanWorkaddictionalcohol cravingalcohol use disorderalcoholism therapybasecostdrug abuserdrug addiction pharmacotherapyimprovedin vivoirritationmeetingspre-clinicalproblem drinkerprototyperesearch and developmentskin irritationsmoking cessationsuccessvaccine development
中文摘要
描述(申请人提供):根据2008年全国药物使用与健康调查(NSDUH),720万美国人需要治疗物质相关障碍(SRD),其中很大一部分人需要治疗阿片类止痛药、海洛因和酒精成瘾。纳曲酮(NTX)是一种阿片类拮抗剂,目前以口服片剂的形式使用,以帮助阿片成瘾者保持戒毒状态。NTX也被FDA批准用于酒精依赖的治疗。有大量的临床证据表明,NTX治疗在戒烟方面有好处,特别是在女性中。在苯丙胺依赖者中也观察到了非常耐人寻味的临床试验数据,这一点尤其重要,因为甲基苯丙胺依赖没有FDA批准的治疗方案。上世纪90年代,S使用甲氨蝶呤治疗吸毒者的成功率各不相同;然而,目前的临床治疗正在基于人类药物遗传学数据进行优化。该药物30天的仓库注射已被批准用于治疗阿片成瘾和酒精中毒;然而,严重注射部位反应(蜂窝组织炎、脓肿和坏死)的上市后报告最近需要更新患者警告。与其他给药系统相比,透皮给药系统提供了许多改进。贴片不需要吞咽,消除了口腔副作用;也不需要用注射器针头进行皮肤穿孔,消除了疼痛和患者去看医生。通过皮肤渗透,药物可以直接进入体循环,避免首过效应,减少肝损害药物滥用者和酗酒者的胃副作用和肝脏损害效应。对于吸毒者和酗酒者来说,NTX经皮给药是可取的,以帮助减少与口服/仓库注射疗法相关的副作用,并提高依从性。NTX本身并不具备允许治疗性剂量的药物通过人体皮肤屏障的基本物理化学性质。微针强化透皮给药是一种有效且无痛的方法,可增加包括NTX在内的多种药物的皮肤渗透性。微针产品目前正处于疫苗开发的后期临床试验阶段,但这种拟议的产品将是用于多天缓释系统治疗的第一个微针递送系统。我们假设NTX联合微针治疗将提供NTX的治疗性透皮吸收速率。原型贴片的初步筛选将在尤卡坦小型猪的药代动力学研究中完成,以验证体外开发的贴片系统在体内表现良好(剂量范围研究)。这项建议的最终研究将是一组关键的GLP动物皮肤毒理学研究,以评估最终贴片的皮肤刺激性和致敏潜力。这一最终数据将用于申请IND,以便在该项目结束时开始I期临床试验。我们将创造一种适销对路、安全的药物,这将大大有助于成瘾的治疗。
公共卫生相关性:根据2008年全国药物使用与健康调查(NSDUH),720万美国人需要治疗与物质相关的疾病(SRD),其中很大一部分人需要治疗阿片类止痛药和海洛因成瘾。此外,超过8.5%的美国人口和全球7500万人符合酒精使用障碍(AUD)的诊断标准,酒精滥用是美国和世界上三大可预防的公共卫生问题之一。拟议的临床前转化研究将加快通过经皮微针系统给药的纳曲酮测试,以评估其作为改善酒精中毒、阿片类药物和其他药物成瘾药物疗法的主要候选药物的益处。
英文摘要
DESCRIPTION (provided by applicant): According to the National Survey of Drug Use and Health (NSDUH) of 2008, 7.2 million Americans are in need of treatment for Substance-Related Disorders (SRDs), and a large proportion of those need treatment for opiate pain reliever, heroin, and alcohol addiction. Naltrexone (NTX), an opioid antagonist, is currently used in oral tablet form to help maintain opioid addicts in a drug-free state. NTX is also FDA-approved for the treatment of alcohol dependence. Substantial clinical evidence exists for the benefits of NTX treatment in smoking cessation, especially in women. Very intriguing clinical trial data has also been observed in amphetamine-dependent individuals, which is especially important as methamphetamine dependence has no FDA-approved treatment options. Treatment with NTX in the 90's produced variable success rates in addicts; however, current clinical NTX therapy is being optimized based on human pharmacogenetic data. A 30-day depot injection of the drug has been approved for the treatment of opiate addiction and alcoholism; however, postmarketing reports of serious injection site reactions (cellulitis, abscess, and necrosis) have recently required patient warning updates. Transdermal delivery systems offer a number of improvements over other delivery systems. Patches do not require swallowing, eliminating oral side effects; nor do they require skin puncture by syringe needles, eliminating pain and patient visits to a physician. Permeation through the skin allows the drug to directly enter the systemic circulation and avoid the first pass effect, decreasing gastric side effects and liver damage effects in hepatocompromised drug abusers and alcoholics. Transdermal delivery of NTX is desirable for addicts and alcoholics in order to help reduce side effects associated with oral/depot injection therapies and improve compliance. NTX itself does not have the essential physicochemical properties that would allow a therapeutic dose of the drug to cross the human skin barrier. Microneedle-enhanced transdermal delivery is an efficient and painless method for increasing the skin permeation of many drugs, including NTX. Microneedle products are currently in late-stage clinical trials for vaccine development, but this proposed product would be the first microneedle delivery system for multiple day sustained release systemic treatment. We hypothesize that NTX in combination with microneedle treatment will provide a therapeutic transdermal delivery rate of NTX. The initial screening of the prototype patch will be completed in a Yucatan miniature pig pharmacokinetic study to verify that the patch system developed in vitro performs well in vivo (dose ranging study). The final studies for this proposal will be a group of critical GLP dermatotoxicology studies in animals to assess skin irritation and sensitization potential of the final patches. This final data will be used to apply for an IND, so that a Phase I clinical trial may begin at the end of this project. We will create a marketable and safe drug that will significantly aid in the treatment of addiction.
PUBLIC HEALTH RELEVANCE: According to the National Survey of Drug Use and Health (NSDUH) of 2008, 7.2 million Americans are in need of treatment for Substance-Related Disorders (SRDs), and a large proportion of those need treatment for opiate pain reliever and heroin addiction. Additionally, over 8.5% of the U.S. population and 75 million people worldwide meet the diagnostic criteria for alcohol use disorders (AUDs), with alcohol abuse being among the top three preventable public health problems in the U.S. and the world. The proposed preclinical translational research will accelerate testing of naltrexone delivered via a transdermal microneedle system to assess its benefits as a lead candidate in the search for improved alcoholism, opiate, and other drug addiction pharmacotherapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Heat Effect on Generic Transdermal Drug Delivery Systems
-
批准号:9340991
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2013
-
负责人:Audra L. Stinchcomb
-
依托单位:
Microneedle-enhanced codrug delivery for smoking cessation and appetite suppressi
-
批准号:8508902
-
项目类别:
-
资助金额:$23.01万
-
财政年份:2012
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Naltrexone for Opiate Addiction and Alcoholism
-
批准号:8519709
-
项目类别:
-
资助金额:$69.6万
-
财政年份:2012
-
负责人:Audra L. Stinchcomb
-
依托单位:
Microneedle-enhanced codrug delivery for smoking cessation and appetite suppressi
-
批准号:8303925
-
项目类别:
-
资助金额:$20.36万
-
财政年份:2012
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Cannabidiol Prodrug Delivery
-
批准号:8199298
-
项目类别:
-
资助金额:$16.05万
-
财政年份:2011
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal delivery of 2-Arachidonoyl glycerol (2-AG) for the treatment of arthr
-
批准号:8279206
-
项目类别:
-
资助金额:$7.68万
-
财政年份:2011
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal delivery of 2-Arachidonoyl glycerol (2-AG) for the treatment of arthr
-
批准号:8516633
-
项目类别:
-
资助金额:$5.91万
-
财政年份:2011
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Cannabinoid Prodrug Treatment for Cannabis Withdrawal and Dependence
-
批准号:7943910
-
项目类别:
-
资助金额:$193.25万
-
财政年份:2009
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Delivery of Buprenorphine Prodrugs
-
批准号:7611813
-
项目类别:
-
资助金额:$11.5万
-
财政年份:2009
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Cannabinoid Prodrug Treatment for Cannabis Withdrawal and Dependence
-
批准号:7861337
-
项目类别:
-
资助金额:$208.07万
-
财政年份:2009
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Codrugs for Treatment of Alcoholism
-
批准号:7024607
-
项目类别:
-
资助金额:$35.96万
-
财政年份:2003
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Codrugs for Treatment of Alcoholism
-
批准号:6710705
-
项目类别:
-
资助金额:$36.8万
-
财政年份:2003
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Codrugs for Treatment of Alcoholism
-
批准号:6865678
-
项目类别:
-
资助金额:$36.83万
-
财政年份:2003
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Codrugs for Treatment of Alcoholism
-
批准号:6555545
-
项目类别:
-
资助金额:$36.67万
-
财政年份:2003
-
负责人:Audra L. Stinchcomb
-
依托单位:
Naltrexone Prodrugs for Transdermal Delivery
-
批准号:6623667
-
项目类别:
-
资助金额:$25.34万
-
财政年份:2002
-
负责人:Audra L. Stinchcomb
-
依托单位:
Naltrexone Prodrugs for Transdermal Delivery
-
批准号:6469406
-
项目类别:
-
资助金额:$25.34万
-
财政年份:2002
-
负责人:Audra L. Stinchcomb
-
依托单位:
Naltrexone Prodrugs for Transdermal Delivery
-
批准号:6711688
-
项目类别:
-
资助金额:$25.34万
-
财政年份:2002
-
负责人:Audra L. Stinchcomb
-
依托单位:
Naltrexone Prodrugs for Transdermal Delivery
-
批准号:7798621
-
项目类别:
-
资助金额:$28.0万
-
财政年份:2002
-
负责人:Audra L. Stinchcomb
-
依托单位:
Naltrexone Prodrugs for Transdermal Delivery
-
批准号:6937298
-
项目类别:
-
资助金额:$6.15万
-
财政年份:2002
-
负责人:Audra L. Stinchcomb
-
依托单位:
Naltrexone Prodrugs for Transdermal Delivery
-
批准号:7597157
-
项目类别:
-
资助金额:$31.07万
-
财政年份:2002
-
负责人:Audra L. Stinchcomb
-
依托单位:
海外基金